만성 정신분열증 환자의 Risperidone 치료효과와 안전성
The Efficacy and Safety of Risperidone (R 64 766) in the Treatment of Chronic Schizophrenic Patients
박민철, 피상순, 이상렬,
소속 상세정보
박민철 ( Park Min-Cheol )
Wonkwang University College of Medicine Department of Neuropsychiatry
피상순 ( Pi Sang-Soon )
Wonkwang University College of Medicine Department of Neuropsychiatry
이상렬 ( Lee Sang-Yeul )
Wonkwang University College of Medicine Department of Neuropsychiatry
KMID : 0361519950060010089
Abstract
This open study was designed to investigate the efficacy and safety of risperidone. The subjects consisted of 20 patients with chronic schizophrenia by DSM-III-R(8 males, 12 females), who were treatment resistant with classical antipsychotics.
After a
one-week wash-out period, 20 chronic schizophrenic renic patients were treated with risperidone for four months. The patients psychopathology was assessed by means of Positive and Negative Syndrome Scale for Schizophrenia(PANSS) and the Clinical
Global
Impression(CGl). Clinical improvement was defined as at least 20% reduction in baseline score on the PANSS. Safety assessments included the Extrapyrmidal Symptom Rating Scale(ESRS), the UKU Side Effect Rating Scale, vital signs, body weight, ECG
and
laboratory screening. Eighteen patients completed the trial. Mean daily dose of risperidone at endpoint was 9.1mg. The number of patients with a clinical improvement after 4 months on the PANSS was 10(58.8%). For severity of illness on the CGI
after 4
months, 8(47.1%) patients scored mild and mean score was 2.9. The severity of extrapyramidal symptoms didn’t increase during open risperidone treatment. No relevant changes in blood pressure or clinical laboratory parameters were observed, except
for a
mean increase of 2.0kg in body weight. This study has demonstrated that the combined serotonin 5-HT2 and dopamine-D2 antagonist risperidone is a new potent antipsychotic drug and causes less extrapyramidal symptoms and other side effects.
키워드
원문 및 링크아웃 정보
등재저널 정보